TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02188160
Drug: KPI-121
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study: NCT02188160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Study: NCT02489513
Drug: [14C]-AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labeled investigational drug
Study: NCT00009841
Drug: DC-cholesterol liposome
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00294554
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
Study: NCT00862355
Drug: SPARC147609
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00862355
Drug: Reference147609
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00747877
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00916578
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
Study: NCT01856166
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02986334
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
Study: NCT02986334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
Study: NCT01012843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Placebo tablets two times a day for 10 days
Study: NCT00480584
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2
Study: NCT02987868
Drug: Placebo first day
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Study: NCT02987868
Drug: Placebo second day
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Study: NCT01727622
Drug: FDG-PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic: FDG-PET imaging to examine neuronal health
Study: NCT00184821
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01093521
Drug: 100 mg/m2 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
Study: NCT00982215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
Study: NCT00744185
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
Study: NCT03092895
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive FOLFOX4 treatment every 2 weeks
Study: NCT01092624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Study: NCT02656043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03406260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00353379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take placebo for 6 weeks.
Study: NCT02237079
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo tablet
Study: NCT03088059
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
Study: NCT03088059
Drug: IPH2201
Approvals — FDA: no, EMA: no, PMDA: no
Description: protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Study: NCT01057498
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNS60, 4ml nebulized twice daily for 15 minutes.
Study: NCT01057498
Drug: RNS60 - single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNS60, single 4 ml dose nebulized for 15 minutes
Study: NCT00683176
Drug: Choline Fenofibrate
Normalized name: Choline Fenofibrate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 135 mg
Study: NCT00683176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01757015
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 (50µg, o.d. via SDDPI) in the morning,
Study: NCT01757015
Drug: Placebo to NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to NVA237
Study: NCT03571503
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Study: NCT04150835
Drug: Xingnaojing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Study: NCT04150835
Drug: Xingnaojing placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Study: NCT04294069
Drug: Azithromycin 500 mg
Normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg azithromycin PO for seven days starting on admission
Study: NCT04294069
Drug: Azithromycin Oral Product
Normalized name: azithromycin Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg azithromycin PO once at admission
Study: NCT00568802
Drug: Placebo to match hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03717194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
Study: NCT02777723
Drug: Xenobella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic 0.3% Sodium Hyaluronate
Study: NCT04111965
Drug: Nanodrop®
Approvals — FDA: no, EMA: no, PMDA: no
Description: minimum to meet 1 drop 4 times a day, both eyes
Study: NCT00548327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
Study: NCT02027935
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00052039
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study was terminated prior to enrollment.
Study: NCT00002557
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03571594
Drug: ONO-5788 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00002557
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002557
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002557
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02019355
Drug: 5-fluorouracil 5% cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05104931
Drug: Nanoformed Piroxicam IR Tablet
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally delivered Nanoformed Piroxicam
Study: NCT05104931
Drug: Felden (piroxicam) Tablets
Normalized name: piroxicam Oral Capsule [Feldene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally delivered Felden (reference) tablets
Study: NCT05104931
Drug: Brexidol (piroxicam) Tablets
Normalized name: piroxicam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally delivered Brexidol (reference) tablets
Study: NCT00006480
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00375752
Drug: Zolendronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
Study: NCT03369782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex
Study: NCT01104649
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
Study: NCT04326374
Drug: daily hGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous injection
Study: NCT02169882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs.
Study: NCT00690820
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00565474
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graft vasculopathy
Study: NCT00662909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01269294
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of 75 mg once daily for 7 days in Treatment A
Study: NCT01269294
Drug: Placebo for TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 placebo capsules once daily for 7 days in Treatment C
Study: NCT01269294
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
Study: NCT01269294
Drug: Placebo for TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules once daily for 7 days in Treatment A
Study: NCT01269294
Drug: Placebo for TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 placebo capsules once daily for 7 days in Treatment D
Study: NCT01140906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, daily, orally
Study: NCT02112734
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo daily
Study: NCT02397525
Drug: LIPO-202
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00947544
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
Study: NCT00947544
Drug: NaPBA
Normalized name: Caffeine 200 MG Oral Powder for Suspension [SNAPBACK STIMULANT POWDERS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
Study: NCT00299039
Drug: acetaminophen plus codeine
Normalized name: acetaminophen / codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules four times daily until pain free or for a maximum of seven days
Study: NCT00299039
Drug: acetaminophen plus ibuprofen
Normalized name: acetaminophen / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules four times daily until pain free or for a maximum of seven days
Study: NCT00026130
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
Study: NCT01917019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets
Study: NCT03257267
Drug: Investigator Choice (IC) Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC chemotherapy options include:~1. Antifolate: Pemetrexed~2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan~3. Nucleoside analogue: Gemcitabine~4. Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above.
Study: NCT01563939
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg.
Study: NCT00744341
Drug: SLV320
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25mg i.v. bid
Study: NCT00744341
Drug: SLV320
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75mg i.v. bid
Study: NCT00744341
Drug: SLV320
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg i.v. bid
Study: NCT00744341
Drug: SLV320
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.0mg i.v. bid
Study: NCT00744341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01874860
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline capsule, 100 mg, taken twice daily
Study: NCT01874860
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recommended for daily use if rash returns (Topical cream)
Study: NCT02107274
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
Study: NCT02107274
Drug: Placebo for Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
Study: NCT03531905
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, matched for the FDC product for blinding purposes
Study: NCT00756470
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
Study: NCT03531905
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo over-encapsulated for blinding purposes
Study: NCT01400100
Drug: sterile NaCl (sodium chloride) 0,9% solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
Study: NCT00132626
Drug: [123I]ß-CIT and SPECT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01060501
Drug: Folinic Acid, interferon-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
Study: NCT00038792
Drug: Recombinant Human Keratinocyte Growth Factor
Normalized name: Recombinant human keratinocyte growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215460
Drug: FMS placebo rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study: NCT02215460
Drug: FMS azithromycin tablets
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study: NCT02215460
Drug: FMS placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study: NCT02215460
Drug: QS azithromycin tablets
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study: NCT02215460
Drug: QS placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study: NCT01251614
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
Study: NCT01251614
Drug: Placebo to Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once a week
Study: NCT02892409
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablets
Study: NCT02215460
Drug: QS placebo rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study: NCT00302419
Drug: intracoronary infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: streptokinase, 250,000 units
Study: NCT02609490
Drug: Azilsartan placebo tablets
Normalized name: azilsartan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT00058981
Drug: DiaPep277
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00189033
Drug: psyllium fibre (dietary supplement)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01548157
Drug: HCP1007 / omarco and crestor
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCP1007 / Rosuvastatin plus Omega-3
Study: NCT00666770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo 30 minutes prior to bedtime
Study: NCT00751127
Drug: PhXA41
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in the affected eye once daily for six months.
Study: NCT03098979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once daily for 20 weeks
Study: NCT02426684
Drug: IdeS® (Imlifidase)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24mg/kg IdeS
Study: NCT00259831
Drug: CVT-E002 (Cold-FX); a natural health product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01715298
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
Study: NCT01715298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder for inhalation in single-dose capsules (matching those for NVA237).